Conditioning regimens for allogeneic hematopoietic stem cell transplants in acute myeloid leukemia

Bone Marrow Transplantation
Y S JethavaA Bacigalupo

Abstract

AML is currently the first indication for allogeneic hematopoietic stem cell transplantation (allo-HSCT), as shown by international transplant registries. The conditioning regimens are classified as myeloablative conditioning, non-myeloablative or reduced intensity conditioning. Targeted radioimmunotherapy such as anti-CD45 antibody have also been added to the conditioning regimen in an attempt to improve tumor cell kill. Refinement of standard regimens has led to a reduction of non-relapse mortality, also in the older age group over 60 or 70 years of age. Relapse post allo-HSCT remains an important issue, especially for patients who undergo transplant with residual or refractory disease. In these patients, pre- and post-transplant interventions need to be considered.

References

Jan 1, 1992·International Journal of Radiation Oncology, Biology, Physics·F B PetersenK M Sullivan
Apr 1, 1988·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S RiddellE D Thomas
May 1, 1982·International Journal of Radiation Oncology, Biology, Physics·E D ThomasR Storb
Dec 24, 1997·Bone Marrow Transplantation·H GondoY Niho
Aug 13, 2002·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·P V O'DonnellE J Fuchs
Dec 14, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ute HegenbartRainer Storb
Mar 1, 2006·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Jeffrey Y C WongGeorge Somlo
Dec 7, 2006·Blood·Bipin N SavaniA John Barrett
Mar 6, 2007·Best Practice & Research. Clinical Haematology·Charles Linker
Aug 12, 2008·Current Clinical Pharmacology·Christa Ellen Nath, Peter John Shaw
Nov 10, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Andrea BacigalupoMary Horowitz
May 5, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Boglarka GyurkoczaBrenda M Sandmaier
Jun 2, 2010·Haematologica·Jacopo Peccatori, Fabio Ciceri
Jan 15, 2011·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Betul OranClaudio G Brunstein
Sep 29, 2011·Current Opinion in Hematology·William ArceseAlessandra Picardi
Sep 4, 2012·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Anna Maria RaiolaAndrea Bacigalupo
Nov 7, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Je-Hwan LeeKyoo-Hyung Lee
Feb 2, 2013·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Jennifer A KanakryRichard F Ambinder
Feb 19, 2013·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Doris M PonceJuliet N Barker
Jan 21, 2014·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Boglarka GyurkoczaHans Joachim Deeg
Jun 17, 2014·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Raynier DevillierDidier Blaise
Jul 22, 2014·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Olle RingdénNavneet S Majhail
Sep 17, 2014·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Avichai Shimoni
Sep 30, 2014·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Antonio Di StasiStefan O Ciurea

❮ Previous
Next ❯

Citations

May 29, 2018·Cancer·Martha Arellano, Jennifer Wilkinson Carlisle
Oct 30, 2018·American Journal of Hematology·Takaaki KonumaUNKNOWN Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation
Sep 26, 2020·Frontiers in Immunology·Jastaranpreet SinghJuan Carlos Zúñiga-Pflücker
Dec 30, 2020·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Charles CraddockSylvie D Freeman
Mar 17, 2020·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M HeuserUNKNOWN ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org
Oct 24, 2020·Current Stem Cell Reports·Paulina D HortonPamela L Wenzel
Jun 21, 2020·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Maria C B Bittencourt, Stefan O Ciurea
Aug 31, 2021·Hematology, Transfusion and Cell Therapy·Ömer Faruk BahçecioğluAhmet Sarıcı
Oct 6, 2021·Journal of Cancer Research and Clinical Oncology·Regina MühleckUlf Schnetzke
Jun 23, 2021·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Camille Lange, Frank Maldarelli

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.